Provides development, upstream manufacturing and clinical/regulatory management of recombinant therapeutic proteins, including a recombinant human Factor VIIa program in Phase 3 for adults with congenital hemophilia A or B with inhibitors. Delivers full-service biotech development and manufacturing services to partners using proprietary technologies.